33 results about "Infantile hemangioma" patented technology

The invention discloses application of external timolol preparations in treating infantile hemangioma and a preparation method thereof, belongs to the field of pharmacy and aims to providing various timolol preparations supportive of external use and used for treating infantile hemangioma. Various external preparations like gels, plastics, paste and pigmentum can be prepared by adding proper auxiliary materials like gel substrate, percutaneous penetration enhancer, preservative, humectant, emulsifier, film forming material and oily substrate. The external timolol preparations have the advantages of high safety, accurate curative effect, high tolerance and quickness in taking effect.

The invention relates to a timolol long-acting transdermal preparation, comprising the following preparation processes: firstly preparing timolol into a timolol nano-drug or timolol micro-powder, and then preparing the timolol nano-drug or timolol micro-powder into a timolol hydrogel transdermal preparation, an ointment transdermal preparation or a micro-needle transdermal preparation. The invention also relates to an application of the drug in hemangioma treatment. When used for treating infantile hemangioma, the medicine disclosed by the invention is capable of improving the medicine absorption efficiency of the pathological cells, and therefore the treatment effect is improved, the dosage is lowered, and no adverse reactions are generated in the treatment process.

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.

The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.

The invention discloses a propranolol hydrochloride cream used for treating infantile hemangioma, and a preparation method thereof. The cream comprises the components of, by weight, 0.8-1.2% of propranolol hydrochloride, 5.5-8% of octadecanol, 5.5-8% of glycerol monostearate, 5.5-8% of stearic acid, 7.5-10.5% of liquid paraffin, 7.5-10.5% of glycerol, 7.5-10.5% of propylene glycol, 1.5-2.5% of an emulsifier, 0.4-0.6% of a penetration enhancer, 0.08-0.12% of a preservative, and balance of water. The propranolol hydrochloride cream provided by the invention has good stability, and an effective duration of at least 24 months. The cream can directly act upon an infection site, such that local medicine concentration is high, and adverse reactions caused by oral administration or intravenous administration can be avoided. With the cream, medicine effect can be maximized, and medicine side effect can be reduced. The cream has a definite effect, and is suitable for industrialized large-scale productions. The cream is used for treating hemangioma and is especially suitable for treating infantile hemangioma.

The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.

The invention provides gel for infantile hemangioma and a preparation method of the gel, and belongs to the technical field of pharmaceutical preparations. The gel for infantile hemangioma consists ofpropranolol, timolol maleate, NVP-Gelbert alcohol maleate monoester copolymer, vaseline, liquid paraffin, glycerin monostearate, lauryl sodium sulfate, glycerinum, ethylparaben and water. The gel forhemangioma has the advantages of being easy to prepare, convenient to use, capable of taking effect fast, long in acting time, remarkable in treatment effect and the like, the acting time of the drugis prolonged through the NVP-Guerbet alcohol maleate monoester copolymer, the biocompatibility of the drug is improved, and the advantage of controlled release is achieved. The gel for hemangioma issuitable for industrial large-scale production and used for treating infantile hemangioma.

The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

The invention belongs to the field of medicine, specifically relates to an novel application of itraconazole, and provides a novel application of itraconazole in the preparation of drugs for treating hemangioma. Itraconazole can effectively inhibit the proliferation and migration performance of endothelial cells of hemangioma, has a good pharmaceutical value, can be used to treat hemangioma in clinic especially strawberry hemangioma, cavernous hemangioma, plexiform hemangioma, verrucous hemangioma, and mixed hemangioma, and can also treat hemangioma of each organ such as liver hemangioma, spleen hemangioma, brain hemangioma, and the like. A novel choice is provided for treating diseases of blood vessel excessive proliferation and blood vessel malignant proliferation, such as hemangioendothelioma, hemangiopericytoma, glomangioma, hemangiosarcoma, angiofibroma, angiolipoma, angiokeratoma, spider nevus, vascular malformation, telangiectasis, infantile hemangioma, adult hemangioma, senile hemangioma, Kaposi's sarcoma, and the like.

The invention belongs to the technical field of drug preparation and particularly relates to nadolol gel for treating infantile hemangioma and a preparation method thereof. The nadolol gel for treating infantile hemangioma comprises, by weight: 1.0-4.0 parts of nadolol, 0.5-2.0 parts of carbomer, 0.2-0.8 part of sodium hydroxide, 1.5-4.5 parts of propylene glycol, 0.1-0.2 part of ethylparaben, 4.0-8.0 parts of glycerol and the balance of water. Compared with the prior art, the nadolol gel for treating infantile hemangioma has good therapeutic effect, is convenient to use, is used at low dosage, rarely accumulates in the human body, and has small side effect.

The invention discloses a traditional Chinese medicinal composition for treating infantile hemangiomas as well as a preparation and a preparation method thereof. The traditional Chinese medicinal composition comprises the following substances in parts by weight: 1-5 parts of kelp, 1-5 parts of seaweed, 1-5 parts of red-rooted salvia, 1-5 parts of red peony root, 1-5 parts of angelica, 1-5 parts ofrehmannia, 1-5 parts of radix scrophulariae and 1-5 parts of turmeric. With the kelp and the seaweed as monarch medicines, the traditional Chinese medicinal composition fundamentally activates bloodcirculation, removes blood stasis, dissolves phlegm and induces diuresis so as to fundamentally control the disease; with the red-rooted salvia and the red peony root as ministerial medicines, the ministerial medicines supplement the monarch medicines to achieve the efficacies of activating the blood circulation and removing the blood stasis, and have the efficacies of clearing away heat and toxicmaterials; with the angelica and the rehmannia as adjuvant medicines, the adjuvant medicines adjust the body immunity and improve the medicinal effect; with the radix scrophulariae and the turmeric as conductant medicines, the conductant medicines supplement the monarch medicines and the ministerial medicines; according to a formula, various medicines are combined, the monarch medicines and the ministerial medicines cooperate with one another, and the ministerial medicines and the ministerial medicines jointly achieve the supplementing effect, so that the traditional Chinese medicinal composition can effectively treat skin hemangiomas; in addition, the hemangiomas are unlikely to relapse, and the total effective rate reaches 97.5%; the traditional Chinese medicinal composition uses natural Chinese herbs as raw materials and is exact in therapeutic effect and free of toxic and side effects.

The invention provides a timolol maleate liposome gel and a preparation method thereof. The gel is prepared from timolol maleate, a penetration enhancer, a humectant, a preservative, a liposome forming agent, a gel matrix, a pH regulator and medical purified water. The prepared timolol maleate liposome gel is uniform and delicate, suitable in viscosity and easy to spread, the drug release time is prolonged through the liposome technology, the concentration of the drug at the diseased region is kept, the gel is used for treating infantile hemangioma, drug administration is convenient, meanwhile, the first-pass effect of the liver is avoided, and meanwhile the gel is convenient to use, high in safety, simple in production process and good in application prospect.

Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.

Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.

The invention provides an angioma gel containing amphiphilic polymers and a preparation method of the angioma gel and belongs to the technical field of medicine preparations. The angioma gel containing amphiphilic polymers is prepared from propranolol or timolol maleate, NVP-maleic docosanol monoester copolymer, tween-80, lauryl sodium sulfate, propylene glycol, silicone oil, vaseline, acetone chloroform and pure water. The angioma gel has the characteristics of simple preparation, convenience in use, quick response, long acting time, remarkable treatment effect and the like, wherein the NVP-maleic docosanol monoester copolymer can increase the medicine acting time and improve the medicine biocompatibility, has the advantage of sustained release and can reduce use of a transdermal enhancer. The angioma gel is applicable to industrial large-scale production and is used for treating infantile hemangioma.

The invention provides a hemangioma gel containing an amphiphilic polymer and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The invention provides a hemangioma gel containing an amphiphilic polymer, which is composed of propranolol or timolol maleate, NVP-maleic acid monodocosanol monoester copolymer, Tween-80 , sodium lauryl sulfate, propylene glycol, silicone oil, vaseline, chlorobutanol and purified water; the hemangioma gel has the characteristics of simple preparation, convenient use, quick onset, long acting time, and remarkable therapeutic effect. NVP ‑Docosanol monoester maleate copolymer increases the action time of the drug, improves the biocompatibility of the drug, has the advantages of slow and controlled release, and reduces the use of transdermal accelerators; the hemangioma coagulation agent of the present invention The glue is suitable for industrialized large-scale production and is used for treating infantile hemangioma.

The invention belongs to the technical field of medicines, and discloses atenolol gel used for treating infantile hemangioma, a preparation method and applications. The atenolol gel used for treating infantile hemangioma includes 5% of atenolol gel. The atenolol gel consists of atenolol and solid gel. The content of the atenolol in each gram of the atenolol gel is 50 mg. The preparation method of the atenolol gel includes obtaining the atenolol gel by mixing 50 mg of the atenolol and the solid gel. The atenolol gel can be used for treating infantile hemangioma, and is good in treatment effect, less in adverse reaction, wide in indication; and the atenolol gel is longer in half life, less in drug use frequency, better in medical compliance, and lower in cost. By using the atenolol gel to treat the hemangioma in an external use manner, risks of adverse reactions, such as gastrointestinal discomfort (diarrhea) and mood changes, caused by oral drugs can be avoided.

The invention discloses itraconazole drops and a preparation method thereof. The itraconazole drops are prepared from components in parts by weight as follows: 1-3 parts of itraconazole, 80-120 partsof vitamin E acetate, 5-15 parts of vitamin A1 and 10-30 parts of PEG400. According to the itraconazole drops, itraconazole is in a dissolved state, has good stability, can be directly absorbed instead of being dissolved in gastrointestinal tracts and can improve the biocompatibility. Besides, the preparation technology is simple, auxiliary materials are high in safety, and the itraconazole dropscan be taken with milk or added to milk to be taken and are particularly applicable to treatment of infantile hemangioma.

The invention discloses an itraconazole drop and a preparation method thereof, comprising the following components: 1-3 parts by weight of itraconazole, 80-120 parts by weight of vitamin E acetate, 5-15 parts by weight of vitamin A1, 10-30 parts by weight of PEG400. In the itraconazole drops disclosed in the invention, the itraconazole is in a dissolved state and has good stability, and can be directly absorbed without a dissolution step in the gastrointestinal tract, which is beneficial to improve bioavailability. In addition, the preparation process is simple, the auxiliary materials are high in safety, can be administered with milk or added to milk for administration, and is especially suitable for the treatment of infantile hemangioma.

The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.

The invention relates to a compound propranolol hydrochloride oral liquid for treating hemangioma in children, which comprises the following raw materials by weight: 100-300g of Gallus gallis, 200-400g of Hawthorn, 100-300g of Snakeberry, and 200-300g of Purple Pearl Leaf , Salvia miltiorrhiza 200-400g, lotus leaf 100-300g and propranolol hydrochloride 30-50g; Compared with the prior art, the present invention has significantly improved quality and effect, high cure rate, low adverse reaction rate, and good mouthfeel , easy to administer to children, small dosage, good bioavailability, and huge social and economic benefits.

The present invention belongs to the field of pharmaceuticals, and relates in particular to a new use of itraconazole, specifically a new use of itraconazole in the preparation of a drug treating hemangiomas. The utilisation of itraconazole to treat hemangiomas effectively inhibits hemangioma endothelial cell proliferation and migration capability, has a good medicinal value, and provides a new option for the clinical treatment of hemangiomas, especially strawberry hemangiomas, cavernous hemangiomas, tufted hemangiomas, verrucous hemangiomas and mixed hemangiomas, hemangiomas of various organs of the body such as hepatic hemangiomas, splenic hemangiomas and cerebral hemangiomas, hemangioendotheliomas, hemangiopericytomas, paragangliomas, hemangiosarcomas, angiofibromas, angiolipomas, angiokeratomas, spider nevi, vascular malformations and telangiectasias, and excessive and malignant proliferative diseases of blood vessels such as infantile hemangiomas, adult hemangiomas, senile hemangiomas and Kaposi's sarcomas.

The invention discloses a propranolol hydrochloride cream used for treating infantile hemangioma, and a preparation method thereof. The cream comprises the components of, by weight, 0.8-1.2% of propranolol hydrochloride, 5.5-8% of octadecanol, 5.5-8% of glycerol monostearate, 5.5-8% of stearic acid, 7.5-10.5% of liquid paraffin, 7.5-10.5% of glycerol, 7.5-10.5% of propylene glycol, 1.5-2.5% of an emulsifier, 0.4-0.6% of a penetration enhancer, 0.08-0.12% of a preservative, and balance of water. The propranolol hydrochloride cream provided by the invention has good stability, and an effective duration of at least 24 months. The cream can directly act upon an infection site, such that local medicine concentration is high, and adverse reactions caused by oral administration or intravenous administration can be avoided. With the cream, medicine effect can be maximized, and medicine side effect can be reduced. The cream has a definite effect, and is suitable for industrialized large-scale productions. The cream is used for treating hemangioma and is especially suitable for treating infantile hemangioma.

The invention relates to a pharmaceutical composition for external use. The pharmaceutical composition is characterized by simultaneously containing timolol and allantoin, wherein, timolol can be a free alkali form, and also can be an any pharmaceutically acceptable salt form. The composition preparation has good stability and permeability, and has obvious curative effect for infantile hemangioma.

The invention relates to an application of butyryl timolol in preparation of a medicine for treating superficial, mixed or deep infant hemangioma.

The invention belongs to the technical field of biology, and discloses an application of a glycolytic pathway key enzyme in infantile hemangioma, the glycolytic pathway key enzyme is highly expressed in IH proliferation period tissue and hemangioma endothelial cells, and proliferation and migration of HemEC can be inhibited and apoptosis can be promoted by inhibiting the activity of the key enzyme phosphofructokinase-2 / fructose-2, 6-diphosphatase 3. The identification method comprises the following steps: carrying out immunohistochemical analysis on the expression of glycolysis key enzyme in IH proliferation stage tissue and degradation stage tissue, analyzing the expression conditions of HemEC and umbilical vein endothelial cells, and detecting the proliferation, migration and apoptosis capabilities of the HemEC after the inhibitor intervenes in PFKFB3 expression. According to the invention, the expression condition and the effect of a glycolysis pathway key enzyme in IH are determined, the pathological mechanism of IH occurrence and development is disclosed, and an experimental basis is provided for IH treatment taking glycolysis as a target spot.

The invention discloses an application of artesunate in the preparation of medicines for treating infantile hemangioma. The medicines can fundamentally treat the hemangioma from the pathogenesis against hemangioma forming pathologic mechanisms, have small side effects, do not cause local embolism or severe necrosis of normal tissues, and can obviously reduce the clinic treatment cost because of the low price of the artesunate.

The invention provides a propranolol hydrochloride gel preparation for external use and a preparation method and application thereof. The propranolol hydrochloride gel preparation for the external use contains at least 3% by weight of propranolol hydrochloride. The propranolol hydrochloride gel preparation for the external use has good stability and skin permeability and has a significant curative effect on treatment and prevention of infantile hemangioma located in different subcutaneous depths.